A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages

Rupam Tripura, Thomas J Peto, Nguon Chea, Davoeung Chan, Mavuto Mukaka, Pasathorn Sirithiranont, Mehul Dhorda, Cholrawee Promnarate, Mallika Imwong, Lorenz von Seidlein, Jureeporn Duanguppama, Krittaya Patumrat, Rekol Huy, Martin P Grobusch, Nicholas P J Day, Nicholas J White, Arjen M Dondorp, Rupam Tripura, Thomas J Peto, Nguon Chea, Davoeung Chan, Mavuto Mukaka, Pasathorn Sirithiranont, Mehul Dhorda, Cholrawee Promnarate, Mallika Imwong, Lorenz von Seidlein, Jureeporn Duanguppama, Krittaya Patumrat, Rekol Huy, Martin P Grobusch, Nicholas P J Day, Nicholas J White, Arjen M Dondorp

Abstract

Background: The increase in multidrug-resistant Plasmodium falciparum in Southeast Asia suggests a need for acceleration of malaria elimination. We evaluated the effectiveness and safety of mass drug administration (MDA) to interrupt malaria transmission.

Methods: Four malaria-endemic villages in western Cambodia were randomized to 3 rounds of MDA (a 3-day course of dihydroartemisinin with piperaquine-phosphate), administered either early in or at the end of the study period. Comprehensive malaria treatment records were collected during 2014-2017. Subclinical parasite prevalence was estimated by ultrasensitive quantitative polymerase chain reaction quarterly over 12 months.

Results: MDA coverage with at least 1 complete round was 88% (1999/2268), ≥2 rounds 73% (1645/2268), and all 3 rounds 58% (1310/2268). Plasmodium falciparum incidence in intervention and control villages was similar over the 12 months prior to the study: 39 per 1000 person-years (PY) vs 45 per 1000 PY (P = .50). The primary outcome, P. falciparum incidence in the 12 months after MDA, was lower in intervention villages (1.5/1000 PY vs 37.1/1000 PY; incidence rate ratio, 24.5 [95% confidence interval], 3.4-177; P = .002). Following MDA in 2016, there were no clinical falciparum malaria cases over 12 months (0/2044 PY) in all 4 villages. Plasmodium vivax prevalence decreased markedly in intervention villages following MDA but returned to approximately half the baseline prevalence by 12 months. No severe adverse events were attributed to treatment.

Conclusions: Mass drug administrations achieved high coverage, were safe, and associated with the absence of clinical P. falciparum cases for at least 1 year.

Clinical trials registration: NCT01872702.

Figures

Figure 1.
Figure 1.
Household-level map of study villages. Each marker represents 1 household. Pink markers indicate households in intervention villages that received mass drug administration during July–September 2015. White markers indicate households in control villages that received mass drug administration during July–September 2016.
Figure 2.
Figure 2.
Study flowchart. One additional hamlet from a control village was included in the final cross-sectional survey in July 2016 and then in the subsequent MDA. Abbreviation: MDA, mass drug administration.
Figure 3.
Figure 3.
Clinical malaria incidence, July 2014–June 2017: before MDA, during the study, and after cross-over treatment in early MDA (intervention) and delayed MDA (control) villages. A and B, Plasmodium falciparum incidence in intervention and control villages, respectively. C and D, Plasmodium vivax incidence in intervention villages and control villages, respectively. Abbreviation: MDA, mass drug administration.
Figure 4.
Figure 4.
Subclinical Plasmodium prevalence detected by quantitative ultrasensitive PCR (uPCR): intervention vs control villages. A, Plasmodium species prevalence by ultrasensitive PCR (uPCR) in intervention villages following 3 rounds of mass drug administration. B, Plasmodium species prevalence by uPCR in control villages. Abbreviations: MDA, mass drug administration; PF, Plasmodium falciparum or mixed P. falciparum infections; Psp, Plasmodium infections, unknown species; PV, Plasmodium vivax infections.

References

    1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619–20.
    1. Dondorp AM, Nosten F, Yi P, et al. . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455–67.
    1. Amaratunga C, Sreng S, Suon S, et al. . Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851–8.
    1. Amaratunga C, Lim P, Suon S, et al. . Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357–65.
    1. Maude RJ, Pontavornpinyo W, Saralamba S, et al. . The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009; 8:31.
    1. Maude RJ, Socheat D, Nguon C, et al. . Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS One 2012; 7:e37166.
    1. World Health Organization. Global plan for artemisinin resistance containment (GPARC). Geneva, Switzerland: WHO, 2011.
    1. Thuy-Nhien N, von Seidlein L, Tuong-Vy N, et al. . The persistence and oscillations of submicroscopic Plasmodium falciparum and vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis 2018. doi:10.1016/S473-3099(18)30046-X.
    1. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev 2013; CD008846.
    1. World Health Organization. Strategy for malaria elimination in the Greater Mekong subregion 2015–30. Geneva, Switzerland: WHO, 2015.
    1. World Health Organization. Eliminating malaria in the Greater Mekong Subregion: united to end a deadly disease. Geneva, Switzerland: WHO, 2016.
    1. Imwong M, Suwannasin K, Kunasol C, et al. . The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis 2017; 17:491–7.
    1. Tripura R, Peto TJ, Veugen CC, et al. . Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia. Malar J 2017; 16:56.
    1. Roberts L. Malaria wars. Science 2016; 352:398–402, 404–5.
    1. Roberts L. The village recruiter. Science 2016; 352:407.
    1. Lim R, Peto TJ, Tripura R, Cheah PY. Village drama against malaria. Lancet 2016; 388:2990.
    1. Imwong M, Hanchana S, Malleret B, Rénia L, Day NP, Dondorp A. High throughput ultra-sensitive molecular techniques to quantity low density malaria parasitaemias. J Clin Microbiol 2014; 52:3303–9.
    1. Valea I, Tinto H, Drabo MK, et al. . FSP/MISAME Study Group An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malar J 2012; 11:71.
    1. Medana IM, Day NP, Sachanonta N, et al. . Coma in fatal adult human malaria is not caused by cerebral oedema. Malar J 2011; 10:267.
    1. Kamau E, Tolbert LS, Kortepeter L, et al. . Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of Plasmodium by amplifying RNA and DNA of the 18S rRNA genes. J Clin Microbiol 2011; 49:2946–53.
    1. Erhart A, Thang ND, Hung NQ, et al. . Forest malaria in Vietnam: a challenge for control. Am J Trop Med Hyg 2004; 70:110–8.
    1. Van Bortel W, Trung HD, Hoi le X, et al. . Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control. Malar J 2010; 9:373.
    1. Thanh PV, Van Hong N, Van Van N, et al. . Epidemiology of forest malaria in central Vietnam: the hidden parasite reservoir. Malar J 2015; 14:86.
    1. Sanh NH, Van Dung N, Thanh NX, Trung TN, Van Co T, Cooper RD. Forest malaria in central Vietnam. Am J Trop Med Hyg 2008; 79:652–4.
    1. Erhart A, Ngo DT, Phan VK, et al. . Epidemiology of forest malaria in central Vietnam: a large scale cross-sectional survey. Malar J 2005; 4:58.
    1. Abe T, Honda S, Nakazawa S, et al. . Risk factors for malaria infection among ethnic minorities in Binh Phuoc, Vietnam. Southeast Asian J Trop Med Public Health 2009; 40:18–29.
    1. von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther 2015; 13:715–30.
    1. PREGACT Study Group. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med 2016; 374:913–27.
    1. Saunders DL, Vanachayangkul P, Lon C; US Army Military Malaria Research Program; National Center for Parasitology, Entomology, and Malaria Control (CNM); Royal Cambodian Armed Forces Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014; 371:484–5.
    1. Landier J, Kajeechiwa L, Thwin MM, et al. . Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res 2017; 2:81.
    1. Pell C, Tripura R, Nguon C, et al. . Mass anti-malarial administration in western Cambodia: a qualitative study of factors affecting coverage. Malar J 2017; 16:206.
    1. Landier J, Kajeechiwa L, Thwin MM, et al. . Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res 2017; 2:81.
    1. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Björkman A. Malaria eradication on islands. Lancet 2000; 356:1560–4.
    1. Newby G, Hwang J, Koita K, et al. . Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg 2015; 93:125–34.
    1. Brady OJ, Slater HC, Pemberton-Ross P, et al. . Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health 2017; 5:e680–7.
    1. World Health Organization. Mass drug administration for falciparum malaria: a practical field manual. Geneva, Switzerland: WHO, 2017.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit